FDA Tells 23andMe to Stop Marketing DNA Kits; 23andMe Says It's Sorry for Being Slow
23andMe's $99 DNA kits can't be advertised for their abilities to detect diseases and conditions without permission from the FDA, the FDA formally told the company on Nov. 22, as reported today by Bloomberg.
Context & Ripple Effects
Bloomberg broke the story the same morning — that the FDA told Google-backed 23andMe to halt sales of its DNA test service for lacking clearance — and by end of day the piece had traveled through the New York Times, CNNMoney, Mercury News and outlets as far afield as NEWS.com.au, an unusually broad pickup for an enforcement letter. The FDA's formal Nov. 22 notice bars the company from advertising the disease- and condition-detection abilities of its $99 kits.
23andMe's response was an admission rather than a fight: the company publicly apologized for being slow to engage with the regulator on how it markets the kits. That framing matters because it concedes the FDA's core claim — that health claims make this a regulated product — while leaving open what the company sells and says going forward.
First-order effects
- 23andMe must immediately strip disease- and condition-detection claims from its $99 kit marketing, cutting the main pitch for a consumer product whose price point depends on volume sales.
- The company now has to negotiate a clearance or approval pathway with the FDA before it can legally advertise what its reports detect.
Second-order effects
- Rival direct-to-consumer genomics sellers face the same regulatory read-across: if 23andMe's health claims required clearance, theirs do too, forcing a choice between seeking FDA sign-off or retreating to ancestry-only messaging.
- Investors in consumer health startups — 23andMe carries Google backing — have to price in a longer, costlier path to market for any product that touches diagnosis.
Third-order effects
- If the pattern holds, the FDA's action becomes the template for how consumer-facing health technology is treated: a service sold over the counter with diagnostic language is a medical device regardless of distribution channel.
- Consumer genomics splits structurally into a regulated medical arm that clears the FDA and an unregulated ancestry-and-entertainment arm, with companies forced to pick which business they are in.
The trend: Direct-to-consumer genetics is being pulled from novelty gadget into FDA-regulated diagnostics, with enforcement letters like this one defining where the line sits.